Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.
about
Pediatric Statin Administration: Navigating a Frontier with Limited DataAssociation of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjectsClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells.Impact of OATP transporters on pharmacokinetics.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.Does simvastatin cause more myotoxicity compared with other statins?Efflux and uptake transporters as determinants of statin response.Transporter-mediated drug-drug interactions.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activatedBiomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
P2860
Q28068014-B535DD34-9F0D-4439-AD4C-6568CB8B2AADQ28748753-5AFE5F9B-ED65-4E0F-93B2-B7D2B0812B63Q30234940-677A1DF3-21B7-456F-9E53-00D6E34E08E0Q30431767-3FC92F14-D169-4691-8958-004504E40DA4Q34612244-F5BAB1E7-B96B-42BA-AE60-0FF3F16913D2Q36687277-917D5DDB-024F-4D16-8FA1-C105473914EFQ37392745-5E94B1EA-05CE-44A3-AE10-95D3E442F6A8Q37634190-84EDEBFB-417D-4F33-9D1E-1959F25A657AQ37724381-BCE01456-E1FE-4321-AF2B-E12AA310FB65Q37905033-7BDD9A9B-15DA-40C8-AA3D-B28BE6399FF3Q37960129-E6C3AB07-5BFD-42CC-A39C-0B573BFA46E1Q38793280-47112237-9D9A-45FB-9666-D025F646ADA0Q38888365-0432A008-A766-4B53-BC3B-30E38ABE80C5Q40198351-47FC34E7-0994-4650-A9B8-E354B05136DEQ42711587-3EF2647D-9654-4656-8F95-F41661B1E51CQ42837781-DD529AF5-8DEC-445B-875D-D149F770B86FQ43571907-EC7CE65C-4AD2-4329-8B39-9663639EDE72Q46645985-D5D00E1D-737D-4F0F-A390-35F387A27911
P2860
Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Substantially elevated levels ...... d renal transplant recipients.
@en
Substantially elevated levels ...... d renal transplant recipients.
@nl
type
label
Substantially elevated levels ...... d renal transplant recipients.
@en
Substantially elevated levels ...... d renal transplant recipients.
@nl
prefLabel
Substantially elevated levels ...... d renal transplant recipients.
@en
Substantially elevated levels ...... d renal transplant recipients.
@nl
P2093
P1476
Substantially elevated levels ...... d renal transplant recipients.
@en
P2093
Christensen H
Hartmann A
P304
P356
10.1016/J.CLPT.2004.07.008
P407
P577
2004-10-01T00:00:00Z